Background: Payment for care provided as part of clinical research has beco
me less predictable as a result of managed care. Because little is known at
present about how entry into cancer trials affects the cost of care for ca
ncer patients, we conducted a matched case-control comparison of the increm
ental medical costs attributable to participation in cancer treatment trial
s. Methods: Case patients were residents of Olmsted County, MN, who entered
phase II or phase III cancer treatment trials at the Mayo Clinic from 1988
through 1994, Control patients were patients who did not enter trials but
who were eligible on the basis of tumor registry matching and medical recor
d review. Sixty-one matched pairs mere followed for up to 5 years after the
date of trial entry for case patients or from an equivalent date for contr
ol patients. Hospital, physician, and ancillary service costs were estimate
d from a population-based cost database developed at the Mayo Clinic. Resul
ts: Trial enrollees incurred modestly (no more than 10%) higher costs over
various follow-up periods, The mean cumulative 5-year cost in 1995 inflatio
n-adjusted U.S. dollars among trial enrollees after adjustment for censorin
g was $46424 compared with $44133 for control patients. After 1 gear, trial
enrollee costs were $24645 compared with $23964 for control patients. Conc
lusions: This study suggests that cancer chemotherapy trials may not imply
budget-breaking costs. Cancer itself is a high-cost illness. Clinical proto
cols may add relatively little to that cost.